title: [A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
abstract: Erlotinib is a selective epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor, which shows favorable antitumor activity against chemorefractory lung carcinoma, especially with EGFR gene mutations. We experienced a case in which oxy- genation and performance status improved in with low-dose erlotinib of 100mg/day administered every other day incidental- ly, although a dose of erlotinib 150mg/day daily is encouraged by the RECIST guideline. A 77-year-old male was diagnosed with bronchioloalveolar carcinoma(BAC)and given first-line combination chemotherapy of carboplatin and pemetrexed. However, antitumor activity was not satisfactory. His performance status(PS)was scored as 2 and home oxygen therapy (HOT)was introduced. As second-line chemotherapy, erlotinib was administered 100mg/day daily. However, the patient took the medication every other day at his own discretion, due to severe eruption and itching sensation. Since this case is classified as a nonmeasurable lesion according to the RECIST guideline, it was difficult to measure antitumor activity by tumor size. But improvement of oxygenation, with a performance status score of 0 and normalization of serum CEA level suggested that erlonitib administration of 100mg/day every other day showed antitumor activity.
authors.affiliation: Dept. of Respiratory Diseases, Yokosuka General Hospital, Uwamachi, Japan.
authors.forename: Kenzo
authors.initials: K
authors.lastname: Yuyama
authors.forename: Hisanori
authors.initials: H
authors.lastname: Matsushita
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Egawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Osawa
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tsubouchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Hirotaro
authors.initials: H
authors.lastname: Miura
mesh_terms: D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy*; D000368:Aged; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride